RedHill Biopharma (RDHL) shares were up Tuesday after the company said it started a phase 2 clinical study of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer.
The 80-patient trial will test the potentially enhancing effect of opaganib in overcoming resistance to standard of care androgen receptor pathway inhibition treatment.
The study is financially backed by Bayer and the Ramsay Hospital Research Foundation, RedHill said.
Price: 6.18, Change: +0.43, Percent Change: +7.48
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。